Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Baxter
AstraZeneca
US Army
McKesson
Farmers Insurance
Deloitte
Fish and Richardson

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LITHIUM CARBONATE

« Back to Dashboard

Clinical Trials for Lithium Carbonate

Trial ID Title Status Sponsor Phase Summary
NCT00000369 Maintenance Therapies in Bipolar Disorders Completed University of Pittsburgh Phase 3 The purpose of this study is to see if adding a regimen of individualized psychotherapy can help bipolar I patients who are on lithium. While having a manic or depressed episode patients will be assigned randomly (like tossing a coin) to receive appropriate medication either with or without additional individual psychotherapy. If a patient responds well, he/she will again be assigned randomly to receive further preventative treatment in which medication will be managed either with continued medication clinic visits alone or with additional individual psychotherapy (the patient may not receive the same additional treatment this time). Patient response to treatment will be evaluated throughout the study. If manic/depressive symptoms return at any point during the study, the patient will be treated with appropriate medication and will continue the study. An individual may be eligible for this study if he/she: Has Bipolar I disorder, is experiencing a manic or depressed episode at the time of study entry, and is at least 18 years old.
NCT00000439 Drug Treatment for Alcoholics With Bipolar Disorder Completed University of Pittsburgh Phase 2 The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder.
NCT00000439 Drug Treatment for Alcoholics With Bipolar Disorder Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder.
NCT00005015 Treatment of Depression in Youth With Bipolar Disorders Terminated National Institute of Mental Health (NIMH) Phase 3 THIS STUDY HAS BEEN DISCONTINUED. The study is designed to evaluate the safety and efficacy of fluoxetine for treating children and adolescents with Bipolar Disorder who are experiencing an episode of major depression while being treated with a mood stabilizer. The study involves a 2-week assessment period. Patients who are on stable, therapeutic doses of lithium or valproate and continue to have depression will be randomized to a 12-week treatment of fluoxetine or placebo. Those who respond favorably to treatment will be followed openly for an 18-week continuation phase.
NCT00063362 Combination Therapy for the Treatment of Bipolar Disorders Terminated National Institute of Mental Health (NIMH) Phase 3 This study will compare triple and double drug regimens in the treatment of patients with depression, hypomania, or mania.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lithium Carbonate

Condition Name

Condition Name for Lithium Carbonate
Intervention Trials
Bipolar Disorder 17
Major Depressive Disorder 4
Amyotrophic Lateral Sclerosis 3
Spinal Cord Injuries 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lithium Carbonate
Intervention Trials
Bipolar Disorder 23
Disease 11
Depressive Disorder 6
Depression 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lithium Carbonate

Trials by Country

Trials by Country for Lithium Carbonate
Location Trials
United States 48
China 13
Canada 7
Israel 3
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lithium Carbonate
Location Trials
Pennsylvania 6
New York 6
Ohio 5
Missouri 3
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lithium Carbonate

Clinical Trial Phase

Clinical Trial Phase for Lithium Carbonate
Clinical Trial Phase Trials
Phase 4 11
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lithium Carbonate
Clinical Trial Phase Trials
Completed 31
Recruiting 13
Terminated 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lithium Carbonate

Sponsor Name

Sponsor Name for Lithium Carbonate
Sponsor Trials
National Institute of Mental Health (NIMH) 5
China Spinal Cord Injury Network 4
Roxane Laboratories 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lithium Carbonate
Sponsor Trials
Other 78
NIH 16
Industry 11
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
AstraZeneca
Citi
Cantor Fitzgerald
Mallinckrodt
Express Scripts
Harvard Business School
Julphar
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.